Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co. Ltd. and aaiPharma Inc., is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the U.S.; this remained the case in May 2006.
Drug evaluation : TA-2711E in the treatment of active distal ulcerative colitis / G. Monteleone, F.A. Caprioli. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 8:5(2007 May), pp. 423-428.
Drug evaluation : TA-2711E in the treatment of active distal ulcerative colitis
F.A. CaprioliUltimo
2007
Abstract
Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co. Ltd. and aaiPharma Inc., is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the U.S.; this remained the case in May 2006.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
